The Interministerial Commission on Drug Prices -the body in charge of authorizing and fixing drug prices in Spain- has made an important step towards transparency this week augmenting the publicized information on the decisions made during their meetings.
Thus, through the briefing notes published by the Ministry of Health, we know which new drugs have been and have not been incorporated into the National Health System, at what price and by what criteria the decision has been made (for example, the huge or scarce pharmaceutical value, the existence of alternatives on the market or the rationalization of public expenditure)
This new measure responds to one of the complaints that the campaign No Es Sano, which Salud por Derecho promotes, has been making for a long time and is a big step towards the pursuit of a more transparent model that puts the population’s health before commercial interests.
You can read more in this Acta Sanitaria article (in Spanish)
